Suzhou Homesun Pharmaceutical Co., Ltd. was established on April 17, 2009. Its first-phase project was completed in November 2011, with a registered capital of 98 million yuan, covering an area of 55,000 square meters and a construction area of 56,000 square meters. The company integrates pharmaceutical research, production, and sales, with main products including active pharmaceutical ingredients (APIs), oral solid dosage forms (tablets, soft capsules, hard capsules, and granules), oral solutions, patches, lyophilized powder injections, small-volume injections, inhalation solutions, and eye drops. Both the API and various dosage form production lines have obtained GMP certification.

The company has obtained over 30 invention patents through R&D, technological innovation, and continuous improvement in production efficiency and product quality, including 2 global patents (PCT patents). It holds 48 domestic trademark authorizations and has been recognized with numerous honors, such as National High-Tech Enterprise certification, Intellectual Property Management System certification, Jiangsu Provincial Engineering Technology Research Center, Jiangsu Provincial Private Science and Technology Enterprise, Jiangsu Provincial Graduate Student Workstation, and National Specialized and Sophisticated "Little Giant" Enterprise. The company collaborates with universities and research institutions, including China Pharmaceutical University, Shanghai Institute of Pharmaceutical Industry, and Soochow University, focusing on the development of specialized drugs for antibacterial, antiviral, respiratory, nervous system, digestive system, anti-inflammatory and analgesic, as well as cardiovascular and cerebrovascular systems. Currently, approved products have entered medical institutions through the national centralized drug procurement system, benefiting human health.